Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients

This data deposition includes the aptamer assay quality statement and R script for reproducing the results associated with the study: Duijvelaar, E., Gisby, J., Peters, J.E. et al. Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients. Nat Commun 15, 744 (2024). 

The source data comprises clinical and proteomics data from 318 hospitalised patients with COVID-19 using 6385 unique plasma proteins (Somascan assay) and can be found here: https://doi.org/10.1038/s41467-024-44986-w

Qualified researchers can request access to additional pseudonymised data and related study documents by contacting Erik Duijvelaar at e.duijvelaar@amsterdamumc.nl, affiliated with Amsterdam University Medical Centers, Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands. Requests will be subject to review, and data will only be shared in accordance with applicable privacy regulations and ethical considerations. Identifying information will be carefully removed to safeguard the confidentiality of study participants. Please allow up to five working days to process and respond to your data access request.